ArticleKidney international reports2025
Comparing Cystatin C Estimated GFR With Creatinine Estimated GFR in Acute Kidney Injury Recovery.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Use of Cystatin C in Tandem with Creatinine to Improve GFR Estimation and Clinical Decision Making.Journal of the American Society of Nephrology : JASN · 2026Review
- Top ten tips to manage patients after acute kidney injury.Clinical kidney journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Current guidelines recommend creatinine-based estimated glomerular filtration rate (eGFRcr) to assess kidney recovery after acute kidney injury (AKI); however, this may be inaccurate because of loss of muscle mass. Cystatin C-based eGFR (eGFRcys) is an alternative that is not similarly affected. In addition, simple calculations (e.g., creatinine muscle index, CMI) incorporating the difference between eGFRcr and eGFRcys may indicate prognosis. We sought to determine whether eGFRcr differs from eGFRcys after AKI and whether CMI is associated with mortality. Methods: The AKI Risk in Derby (ARID) study is a prospective parallel-group cohort study. Hospitalized participants with and without exposure to AKI were matched 1:1 for age, baseline kidney function, and diabetes. eGFRcr and eGFRcys at 3 months after admission were compared in 849 participants. Associations between CMI and outcomes, including mortality, heart failure, and hospitalization were assessed at 5 years. Results: eGFRcys was lower than eGFRcr (53.4, [interquartile range, IQR: 34.3-85.5] vs. 68.4 [IQR: 52.5-84.7] ml/min per 1.73 m Conclusion: There are significant differences at 3 months after AKI in eGFR derived from creatinine versus cystatin C. The magnitude of difference between these estimates is associated with subsequent mortality. Further research is required to determine the optimal approach to patient assessment after AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.